儿童多发性硬化症发病前的医疗保健使用因年龄和性别而异:一项全国性队列研究
Fredrik Sandesjö1,2, Kyla McKay3,4, Ali Manouchehrinia3
1Neuropaediatric Unit, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
BMJ neurology open
|January 1, 2026
概括
在儿科发病多发性硬化症 (MS) 发生之前,医疗保健的使用因年龄和性别而异. 男人显示皮肤相关的访问增加,而女性有更多的瘤访问,表明潜在的MS早期检测标志物.
科学领域:
- 神经学 神经学
- 儿科医学 儿科医学
- 流行病学 流行病学
背景情况:
- 在临床发病之前的医疗保健利用表明多发性硬化症 (MS) 的前期阶段.
- 关于儿科发病性多发性硬化症 (PoMS) 预发性阶段的数据有限,特别是关于特定年龄和性别的模式.
- 了解这些模式对于早期发现PoMS和研究MS机制至关重要.
研究的目的:
- 调查PoMS临床发病前几年的特定年龄和性别的医疗保健利用模式.
- 通过对医疗保健访问和处方的分析来识别PoMS的潜在早期指标.
主要方法:
- 利用瑞典多发性硬化病登记处识别18岁之前患有多发性硬化病的个体.
- 对比233个PoMS病例的医疗保健利用率 (住院,门诊,处方) 与1151个匹配的对照人群在患病前16年内进行比较.
- 分析的数据按发病时的年龄 (12-15岁和16-17岁) 和性别分层.
主要成果:
- 患有PoMS的女性在发病前对瘤进行门诊的比率更高 (RR 3.44-5.73).
- 患有PoMS的男性表现出与皮肤相关的访问率增加 (RR 6.00-11.00) 和皮肤科皮质类固醇处方 (RR 3.12).
- 较年长的青少年 (16-17岁) 有较高的瘤相关的访问率,而较年轻的青少年 (12-15岁) 有较高的神经系统相关的访问率.
结论:
- 在临床症状出现之前,PoMS与不同的年龄和性别特定的医疗保健利用模式有关.
- 研究结果强调了男性的皮肤相关访问增加,女性和老年青少年的瘤相关访问作为潜在的早期迹象.
- 这些见解可以为PoMS的早期检测策略提供信息,并提高对MS病变的理解.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Metabolism
171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
Longitudinal Research
13.0K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
13.0K
Bioavailability Study Design: Healthy Subjects Versus Patients
130
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
130
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
225
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
225
Pharmacokinetics in Pediatric Patients: Drug Distribution
234
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
234
Bioavailability Study Design: Single Versus Multiple Dose Studies
176
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
176


